Other

Biognostik Gesellschaft Fur Biomolekulare Diagnostik Mbh

Georg-Ferdinand Schlingensiepen

Karl-Hermann Schlingensiepen

Reimar Schlingensiepen

Wolfgang Brysch

Ulrich Bogdahn

Antisense-oligonucleotides or effective derivatives thereof hybridizing with an area of a gene coding for transforming growth factor-&#x3b2; (TGF-&#x3b2;) comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 1-56 and 137 or comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 57 to 136 each of the nucleic acids having a DNA- or RNA-type structure.

Antisense-oligonucleotides for the treatment of immuno-suppressive effects of transforming growth factor-&#x3b2; (TGF-&#x3b2;)

Antisense-oligonucleotides or effective derivatives thereof hybridizing with an area of a gene coding for transforming growth factor-&bgr; (TGF-&bgr;) comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 1-56 and 137 or comprising the following nucleic acid sequences identified in the sequence listing under SEQ ID NO. 57 to 136 each of the nucleic acids having a DNA- or RNA-type structure.

Antisense-oligonucleotides for transforming growth factor-&bgr; (TGF-&bgr;)

The present invention is related to an antisense-nucleic acid or effective derivatives thereof hybridizing with an area of the messenger RNA (mRNA) or the DNA, encoding the p185 receptor (also termed c-erbB-2, HER2 or neu), a pharmaceutical composition, comprising an antisense nucleic acid or effective derivatives thereof hybridizing with an area of the messenger RNA (mRNA) or the DNA, encoding the c-erbB-2 receptor as well as the use of said antisense nucleic acids and derivatives thereof for the manufacturing of a pharmaceutical composition for the treatment of neoplasms and/or immune diseases and/or diseases involving pathological angiogenesis.

Growing community of inventors

Gottingen, Germany

Georg-Ferdinand Schlingensiepen